Prescription required. Can not be split. Product of Canada. Shipped from Canada.
Prescription required. Can not be split. Product of Canada. Shipped from Canada.
Prescription required. Can not be split. Product of India. Shipped from Mauritius.
Prescription required. Can not be split. Product of Canada. Shipped from Canada.
Prescription required. Can not be split. Product of India. Shipped from Mauritius.
Viibryd, also known as Vilazodone, is specifically formulated to manage Major Depressive Disorder in adults. Its mechanism focuses on the rebalancing of serotonin levels in the brain, helping to alleviate depressive symptoms. Common side effects include nausea and trouble sleeping, with more severe concerns such as increased suicidal thoughts warranting careful monitoring. It is essential to consult healthcare professionals for precise dosing and to address potential medication interactions or worries during pregnancy. Further exploration offers insight into managing anxiety disorders and user experiences, presenting a detailed view of Viibryd's therapeutic potential.
Viibryd is used to treat Major Depressive Disorder in adults by restoring serotonin balance.
Common side effects include nausea, diarrhea, and trouble sleeping.
Viibryd has a unique dual-action mechanism, enhancing its therapeutic potential.
It offers cost-saving programs and a Confidence Program for consistent access.
Viibryd may also be effective in managing anxiety disorders alongside depression.
To comply with Canadian International Pharmacy Association regulations you are permitted to order a 3-month supply or the closest package size available based on your personal prescription. read more
Viibryd, known chemically as Vilazodone, is an established antidepressant that has been effectively treating Major Depressive Disorder in adults for more than ten years. As a serotonin modulator, Viibryd plays a vital role in rebalancing the levels of serotonin in the brain, a neurotransmitter intimately involved in mood regulation. This action makes it a valuable tool in the arsenal against depression, providing hope and relief to many who suffer from this debilitating condition.
Understanding the side effects of Viibryd is important for healthcare providers and patients alike. Commonly reported side effects include nausea, diarrhea, and trouble sleeping. While these are generally manageable, it's important to be vigilant for more serious concerns such as increased suicidal thoughts or serotonin syndrome, which, though rare, require immediate attention.
For those dedicated to serving others, recognizing the signs of Major Depressive Disorder and the potential benefits of treatments like Viibryd can be life-changing. By promoting awareness and understanding of how Viibryd works and its potential side effects, we can better support individuals struggling with depression, guiding them towards a path of recovery and improved quality of life.
As a selective serotonin reuptake inhibitor (SSRI), Vilazodone, the active component of Viibryd, plays a vital role in the treatment of Major Depressive Disorder in adults, effectively restoring the balance of serotonin levels in the brain to regulate mood. This medical intervention is essential for individuals seeking to alleviate the debilitating symptoms associated with major depressive disorder, offering a path toward emotional stability and improved quality of life.
Viibryd, by virtue of its classification among SSRIs, offers a targeted approach to treatment by focusing on the serotonin system, a key neurotransmitter involved in mood regulation. This specificity not only aids in the effective management of depressive states but also contributes to the medication's profile of side effects, which, while remarkable, are consistent with what is expected within this class of drugs. Common side effects include nausea, diarrhea, and trouble sleeping, which must be weighed against the therapeutic benefits when considering Viibryd for treatment.
The medical use of Viibryd underscores the importance of SSRIs in the contemporary management of major depressive disorder. Its efficacy, combined with a well-documented side effect profile, positions it as a valuable option for adults grappling with depression, highlighting the ongoing advancements in psychiatric medication aimed at enhancing patient outcomes.
Understanding the medical benefits of Viibryd underscores the importance of considering the necessary precautions before commencing its use. When contemplating this medication, it is essential to engage in a thorough discussion with a doctor to ensure its compatibility with one's health status and other medications. Viibryd, recognized for its role in treating major depressive disorder, brings with it the potential for side effects, some of which can have a notable impact on an individual's well-being.
To provide the highest level of care and support to those we serve, it is key to highlight the following precautions:
Inform your doctor of all medications being taken: This includes prescription drugs, over-the-counter medicines, and herbal supplements to avoid harmful interactions.
Discuss pregnancy and breastfeeding: Viibryd may pose risks to the unborn child or nursing baby, necessitating a thorough evaluation of benefits versus risks.
Avoid an abrupt stop of the medication: Gradual discontinuation under a doctor's supervision is essential to prevent severe withdrawal symptoms.
The journey towards recovery from depression is a delicate one, requiring a partnership between the patient and healthcare provider to navigate the complexities of treatment with medications like Viibryd.
How is Viibryd properly administered to guarantee its effectiveness in treating major depressive disorder? Ensuring the best management of this condition requires careful attention to the prescribed regimen of Viibryd, a medication recognized for its efficacy in addressing depressive and anxiety disorders. To minimize side effects and enhance therapeutic outcomes, Viibryd should be taken orally with water, once daily, and preferably alongside food. This method of administration aids in maximizing the medication's absorption and effectiveness.
The dose of Viibryd is tailored to the individual, considering their medical history and response to treatment. Patients must adhere strictly to the prescribed dosage and timing, maintaining consistent levels of the medication in the body for the best results. The Medication Guide provided with Viibryd contains essential instructions that must be followed diligently.
Moreover, ongoing consultation with a healthcare provider is crucial. This partnership allows for the dose adjustment as necessary and ensures that the treatment plan remains aligned with the patient's health needs. By following the guidance of healthcare providers and the instructions in the Medication Guide, patients can navigate the treatment of depression with Viibryd effectively.
While careful adherence to the prescribed regimen of Viibryd is aimed at optimizing treatment outcomes for major depressive disorder, it is equally important to be aware of the severe consequences that may arise from an overdose of this medication. Viibryd overdose can precipitate a range of serious health issues that not only jeopardize the patient's recovery journey but may also lead to life-threatening conditions. Immediate medical attention is vital in managing such situations to mitigate the risks and provide necessary supportive care.
The consequences of a Viibryd overdose are profound and necessitate a compassionate and prompt response:
Serotonin syndrome: A potentially fatal condition characterized by a rapid heart rate, high blood pressure, and a state of confusion, evoking a sense of urgency and concern for the individual's well-being.
Seizures: Uncontrolled electrical disturbances in the brain that can cause significant emotional distress and fear for both the patient and their loved ones.
Abnormal bleeding: A complication that can lead to further health issues, emphasizing the importance of vigilance and care in medication management.
Patients taking Viibryd may experience a range of side effects, from important issues such as diarrhea and nausea to more severe complications like seizures and serotonin syndrome. For individuals dedicated to serving others, understanding these side effects is vital to providing thorough care and support. Common side effects, including dizziness and trouble sleeping, are typically manageable but should not be disregarded as they can impact daily functioning and quality of life.
Serious side effects, such as an increased risk of bleeding, tremors, and memory problems, require immediate attention. Healthcare providers should be notified of these concerns promptly to adjust treatment plans as necessary. The occurrence of very serious side effects like seizures and the development of serotonin syndrome is rare but life-threatening, necessitating urgent medical intervention.
An allergic reaction to Viibryd, though uncommon, should be treated as an emergency. Symptoms such as rash, itching, swelling, and severe dizziness indicate a need for immediate care. It's essential to report side effects, whether common or severe, to a healthcare provider or the FDA to guarantee the safety and well-being of individuals taking Viibryd. Monitoring and reporting enable better management of side effects and contribute to the overall effectiveness of the medication.
Viibryd's label includes critical warnings about the potential for increased suicidal thoughts, particularly in young adults under the age of 24. This medication, while effective in treating major depressive disorder, carries significant risks that must be carefully considered. Health professionals and caregivers must remain vigilant for signs of worsening depression or emergent suicidal thoughts, especially during the initial treatment phase or when adjusting dosages. It is paramount to approach the prescription of Viibryd with a deep sense of responsibility and a commitment to patient safety.
Increased suicidal thoughts in young adults: The stark warning underscores the gravity of monitoring and supporting those we serve, emphasizing the importance of early detection and intervention.
Potential for manic episodes: This possibility calls for a careful assessment of medical history and ongoing observation, ensuring that the treatment aligns with the best interest of the patient.
Increased bleeding risk: This side effect necessitates a thorough review of the patient's medical conditions and current medications, embodying the principle of primum non nocere - first, do no harm.
Choosing to prescribe Viibryd involves a delicate balance between benefits and risks, highlighting the critical role of informed, compassionate care in the management of mental health conditions.
Understanding the potential for drug interactions is vital when prescribing Viibryd, as it can interact with a variety of medications and substances. Healthcare providers must be vigilant in reviewing their patients' medication regimens to avoid adverse effects that may arise from these interactions. Specifically, Viibryd has been known to interact with drugs that cause drowsiness, potentially exacerbating this side effect. This underscores the importance of informing healthcare professionals about all medications currently being taken, including over-the-counter drugs, vitamins, and herbal supplements, to guarantee a harmonious treatment plan.
Moreover, certain medications can impact the efficacy or safety of Viibryd, necessitating adjustments to the dosage or the consideration of alternative treatments. Additionally, substances known to increase the risk of bleeding or bruising require caution when combined with Viibryd, as they may elevate the potential for undesirable bleeding events. Maintaining a detailed list of all products being used is essential in preventing adverse interactions with Viibryd. This proactive approach enables healthcare providers to serve their patients effectively, ensuring that treatment for major depressive disorder is both safe and effective.
Considering the potential risks, the use of Viibryd during pregnancy requires careful evaluation and discussion with healthcare providers. The medication, while effective for treating major depressive disorder, may present challenges when it comes to the health and safety of both the expecting mother and her unborn child. Research and clinical observations have underscored the importance of weighing the benefits against the possible adverse outcomes associated with Viibryd during this critical period.
Pregnancy registry data suggests an association with preterm delivery, which can lead to numerous complications for the newborn, including prolonged hospital stays and developmental challenges.
Newborns exposed to Viibryd in utero may have lower birth weight, a factor that can influence a child's health trajectory long into the future.
Observations have also noted lower Apgar scores in babies born to mothers who used Viibryd during pregnancy, indicating immediate postbirth distress and potentially signaling more profound health issues.
In light of these concerns, healthcare providers and patients are encouraged to engage in open, informed dialogues about the use of Viibryd during pregnancy. Together, they can navigate the complexities of managing maternal mental health while prioritizing the well-being of the developing fetus, making choices that serve the best interests of both.
Delving into the pharmacology of Viibryd, it becomes evident that Vilazodone, its active component, uniquely combines the mechanisms of a serotonin reuptake inhibitor and a 5-HT receptor partial agonist. This dual-action approach not only enhances serotonin activity in the brain by preventing its reuptake but also specifically targets serotonin receptors to modulate their response. Such a pharmacological profile positions Vilazodone as a distinctive option for treating major depressive disorder, potentially offering benefits in terms of efficacy and side effect profile.
The bioavailability of Vilazodone is significantly high at 72% under fed conditions, underscoring the importance of absorption dynamics in its clinical use. Patients are advised to take Viibryd with food to optimize absorption, which in turn maximizes its therapeutic potential by increasing maximum plasma concentration (Cmax) and area under the curve (AUC). This guidance is essential for healthcare providers and patients alike, ensuring that the medication's pharmacokinetic properties are fully leveraged to support effective management of major depressive disorder. Through understanding Viibryd's unique pharmacology, medical professionals can better serve those in need, providing a tailored approach to depression treatment.
The development of Viibryd, a significant advancement in the treatment of major depressive disorder, commenced with its initial creation by Merck KGaA, followed by an acquisition by Forest Laboratories in 2011. This journey underscores the pharmaceutical industry's commitment to addressing the complex needs of individuals suffering from major depressive disorder. Viibryd, as a novel therapeutic option, represents a refined approach to managing this condition, integrating the benefits of serotonin reuptake inhibitors with a more favorable side effect profile.
Innovation in Treatment: Viibryd's development marked a pivotal moment in providing those battling major depressive disorder with an alternative that potentially reduces the burden of side effects commonly associated with traditional serotonin reuptake inhibitors.
Hope for Patients: The approval of Viibryd by the FDA, driven by solid clinical data, offered a new ray of hope for patients seeking effective management of their symptoms with fewer adverse effects.
Continued Research and Development: The journey of Viibryd from its inception to approval highlights the importance of ongoing research and development in the quest to improve quality of life for individuals with major depressive disorder.
This narrative not only informs but resonates deeply with those dedicated to serving patients by offering them more personalized and effective treatment options.
In the domain of treating anxiety disorders, Viibryd has emerged as a promising option due to its efficacy in managing symptoms and its unique mechanism of action as a serotonin modulator. For individuals grappling with the debilitating effects of generalized anxiety disorder and other anxiety-related conditions, this medication stands out not only for its potential to alleviate excessive worry and fear but also for its capacity to address comorbid conditions, such as depression. This dual treatment benefit is particularly valuable for those who serve others in healthcare settings, as it offers a thorough approach to managing both anxiety and depressive symptoms with a single medication.
The use of Viibryd as a serotonin modulator is significant, as it targets the neurotransmitter pathways implicated in both depression and anxiety disorders, offering a holistic strategy for symptom management. This approach is supported by research that underscores its effectiveness in treating generalized anxiety disorder, making it an essential resource for healthcare professionals seeking to provide relief to those burdened by excessive worry and the pervasive impact of anxiety disorders. With its proven efficacy and unique action, Viibryd represents a critical tool in the arsenal against anxiety, enabling practitioners to offer hope and improved quality of life to their patients.
Viibryd stands out among antidepressants due to its unique mechanism as a serotonin modulator, offering a distinct perspective when compared to traditional SSRIs and SNRIs. With Vilazodone as its active ingredient, Viibryd showcases a unique pharmacological profile that not only acts as a serotonin reuptake inhibitor but also as a 5-HT receptor partial agonist. This dual action contributes to its effectiveness in treating major depressive disorder while potentially causing less emotional blunting, a common side effect associated with other antidepressants. This aspect is particularly appealing for individuals seeking to preserve their emotional responsiveness during treatment.
Additionally, Viibryd's bioavailability is significantly high at 72% under fed conditions, suggesting that its absorption and, consequently, effectiveness are enhanced when taken with food. This characteristic distinguishes Viibryd from many of its counterparts, which can have varying degrees of bioavailability and food interaction.
Preserving Emotional Depth: Less emotional blunting means individuals may maintain a fuller range of emotions, fostering genuine connections and interactions.
Unique Treatment Option: Its distinctive action on serotonin receptors offers an alternative pathway for those where traditional options may have failed.
Enhanced Absorption with Meals: Encouraging adherence by integrating medication intake with daily routines, potentially improving therapeutic outcomes.
Exploring user experiences with Viibryd reveals a spectrum of outcomes, from significant symptom improvement to minimized side effects, underscoring its impact on individual treatment journeys. Many users have reported a substantial uplift in their mood and overall mental health, attributing it to Viibryd's unique formulation. Remarkably, the emphasis on taking Viibryd with food has been a beneficial tip for many, aiding in the reduction of gastrointestinal side effects and enhancing medication absorption.
Aspect | User Experiences | Impact on Daily Functioning |
|---|---|---|
Improvement | Significant uplift in mood and reduction in depressive symptoms | Enhanced emotional stability and engagement in daily activities |
Side Effects | Fewer and more manageable compared to other antidepressants | Less interference with daily life, promoting better overall well-being |
Administration (Food) | Taking with food helps minimize side effects | Easier integration into daily routine, improving adherence to treatment |
These experiences underline the importance of personalized care in the management of depression. The positive changes in daily functioning and quality of life, as shared by users, highlight Viibryd as a valuable option in the treatment landscape for those seeking to serve and support individuals battling depression.
Viibryd, a beacon in the tempest of depression, stands strong among antidepressants. With its unique serotonin modulation, it effectively combats depressive and anxiety disorders, offering hope to those seeking to serve and uplift others.
The medication in question is associated with various side effects, including nausea, diarrhea, and insomnia. Serious adverse effects may encompass increased suicidal thoughts and serotonin syndrome. It's essential to report any side effects to healthcare professionals for appropriate management.
Viibryd and Zoloft are both antidepressants utilized in treating depression, with differing mechanisms. While Viibryd acts as a serotonin modulator, Zoloft inhibits serotonin reuptake, offering varied side effect profiles and patient response.
While both utilized in depression management, Wellbutrin primarily targets norepinephrine and dopamine pathways, contrasting Viibryd's serotonin-based mechanism. Their distinct action profiles and side effects necessitate individualized consideration when selecting an appropriate treatment strategy.
Vilazodone
(vil az' oh done)
Viibryd®
A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as vilazodone during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant. Children younger than 18 years of age should not normally take vilazodone, but in some cases, a doctor may decide that vilazodone is the best medication to treat a child's condition.
You should know that your mental health may change in unexpected ways when you take vilazodone or other antidepressants, even if you are an adult over 24 years of age. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; frenzied abnormal excitement; or any other changes in your usual thoughts, mood, or behavior. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.
Your healthcare provider will want to see you often while you are taking vilazodone, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.
Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with vilazodone and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.
No matter your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.
Vilazodone is used to treat depression. Vilazodone is in a class of medications called selective serotonin reuptake inhibitors (SSRIs) and is also a 5HT1A receptor partial agonist. It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance.
Vilazodone comes as a tablet to take by mouth. It is usually taken with food once a day. Take vilazodone at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take vilazodone exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor will probably start you on a low dose of vilazodone and gradually increase your dose, not more than once every 7 days. Vilazodone controls depression but does not cure it. It may take several weeks before you feel the full benefit of vilazodone. Continue to take vilazodone even if you feel well. Do not stop taking vilazodone without talking to your doctor. Your doctor will probably decrease your dose gradually. If you suddenly stop taking vilazodone, you may experience withdrawal symptoms such as dizziness; nausea; headache; confusion; irritability; agitation; difficulty falling asleep or staying asleep; anxiety; extreme tiredness; seizures; pain, burning, or tingling in the hands or feet; or sweating. Tell your doctor if you experience any of these symptoms while you are decreasing your dose of vilazodone or soon after you stop taking vilazodone.
Before taking vilazodone,
tell your doctor and pharmacist if you are allergic to vilazodone, any other medications, or any of the ingredients in vilazodone tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
tell your doctor if you are taking a monoamine oxidase (MAO) inhibitor, such as isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate), or if you have stopped taking one of these medications within the past 14 days. Your doctor will probably tell you that you should not take vilazodone. If you stop taking vilazodone, your doctor will tell you that you should wait at least 14 days before you start to take an MAO inhibitor.
tell your doctor and pharmacist what other prescription and nonprescription medications, and vitamins you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); certain antifungals such as itraconazole (Sporanox) and ketoconazole (Nizoral); antihistamines; aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin, others) and naproxen (Aleve, Naprosyn, others); buspirone (BuSpar); clarithromycin (Biaxin, in PrevPac); diuretics ('water pills'); erythromycin (E.E.S., E-Mycin, Erythrocin); linezolid ; lithium (Eskalith, Lithobid); medications for anxiety, mental illness, or nausea; certain medications for human immunodeficiency virus (HIV) such as indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir); medications for migraine such as almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex), and zolmitriptan (Zomig); medications for seizures such as mephenytoin (Mesantoin); methylene blue; metoclopramide (Reglan); nefazodone; sedatives; selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), paroxetine (Paxil, Pexeva), and sertraline (Zoloft); selective serotonin and norepinephrine reuptake inhibitors (SNRIs) such as desvenlafaxine (Pristiq), duloxetine (Cymbalta), and venlafaxine (Effexor); sleeping pills; tramadol (Ultram); tranquilizers; and tricyclic antidepressants such as amitriptyline, amoxapine (Asendin), clomipramine (Anafranil), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil), nortriptyline (Aventyl, Pamelor), protriptyline (Vivactil), and trimipramine (Surmontil). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with vilazodone, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor what herbal products and nutritional supplements you are taking, especially St. John's wort and tryptophan.
tell your doctor if you have or have ever had bleeding problems, seizures, or liver disease.
tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking vilazodone, call your doctor. Vilazodone may cause problems in newborns following delivery if it is taken during the last months of pregnancy.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking vilazodone.
you should know that vilazodone may make you drowsy and affect your judgment and thinking. Do not drive a car or operate machinery until you know how this medication affects you.
ask your doctor about the safe use of alcoholic beverages while you are taking vilazodone. Alcohol can make the side effects from vilazodone worse.
you should know that vilazodone may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.
Talk to your doctor about eating grapefruit and drinking grapefruit juice while taking this medication.
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Vilazodone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: dry mouth increased appetite heartburn gas dizziness pain, burning, or tingling in the hands or feet uncontrollable shaking of a part of the body unusual dreams tiredness joint pain changes in sexual desire or ability Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately: rash hives swelling difficulty breathing loss of consciousness seizures fever, sweating, confusion, fast or irregular heartbeat, and severe muscle stiffness diarrhea nausea vomiting unusual bleeding or bruising nosebleeds small red or purple dots on the skin hallucinations (seeing things or hearing voices that do not exist) headache difficulty concentrating memory problems weakness problems with coordination increased falls fainting Vilazodone may cause other side effects. Call your doctor if you have any unusual problems while taking this medication. If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom). Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program. It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org
Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription. It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
The content on this page is for informational and educational purposes only and does not constitute professional medical advice. Patients should not use the information presented on this page for diagnosing a health-related issue or disease. Before taking any medication or supplements, patients should always consult a physician or qualified healthcare professional for medical advice or information about whether a drug is safe, appropriate or effective.
